Press Releases & Announcements

ACTG TO PRESENT DATA ON INVESTIGATIONAL NEW COVID-19 TREATMENT AT IDWEEK 2021

Sep 29, 2021

ACTG ANNOUNCES GRADUATION OF NOVEL POLYCLONAL ANTIBODY THERAPY SAB-185 TO PHASE 3 STUDY IN ACTIV-2

Sep 27, 2021

ACTG ANNOUNCES DATA FROM ACTIV-2 STUDY, DEMONSTRATING BENEFIT OF BRII-196 AND BRII-198 IN NON-HOSPITALIZED PARTICIPANTS WITH COVID-19

Aug 26, 2021

ACTG NETWORK SOLICITS FOR MEMBERSHIP TO ITS SCIENCE COMMITTEES

Aug 25, 2021

SMALL CLINICAL TRIALS ADVANCING HIV REMISSION AND CURE - DUE SEPTEMBER 1, 2021

Aug 13, 2021

ACTG LAUNCHES STUDY EVALUATING THE EFFECTS OF AN ARV CHANGE AMONG PEOPLE LIVING WITH HIV WHO EXPERIENCE EXCESSIVE WEIGHT GAIN

Jul 29, 2021

SOLICITATION FOR ACTG SCIENCE COMMITTEE LEADERSHIP POSITIONS

Jul 27, 2021

ACTG ANNOUNCES PUBLICATION OF REPRIEVE SUB-STUDY IN JAMA NETWORK OPEN, PROVIDING INSIGHTS INTO CARDIOVASCULAR DISEASE RISK AMONG PEOPLE LIVING WITH HIV

Jun 30, 2021

ACTG ANNOUNCES CAMOSTAT WILL NOT ADVANCE TO PHASE 3 IN OUTPATIENT TREATMENT STUDY FOR COVID-19

Jun 30, 2021

ACTG LAUNCHES PHASE 1 COMBINATION HIV CURE STUDY

Jun 10, 2021

ACTG ANNOUNCES THE ADDITION OF TWO MONOCLONAL ANTIBODIES TO ACTIV-2 OUTPATIENT TREATMENT STUDY FOR COVID-19

Jun 09, 2021

ACTG HONORS THE 40TH ANNIVERSARY OF HIV/AIDS

Jun 07, 2021